Amedica will present the 12-month CASCADE clinical results tomorrow.
The blinded, randomized clinical trial compares outcomes for spinal fusions between the composite silicon nitride fusion device to PEEK spacers filled with bone autograft.
Amedica's CASCADE includes a central core of cancellous structured ceramic.
Netherlands-based Mark P. Arts, MD, will present the findings and Amedica Chairman and CEO Sonny Bal, MD, will discuss the study's potential impact on Amedica's business.